RHHBF Quote, Financials, Valuation and Earnings

EvoNext Holdings SA has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat EvoNext Holdings SA's return on equity of --.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -90.33%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than EvoNext Holdings SA, analysts believe Roche Holding AG is more attractive than EvoNext Holdings SA.

Roche Holding AG has a beta of 0.270, which suggesting that the stock is 72.997% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -42.013, suggesting its less volatile than the S&P 500 by 4301.301%.

Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.22%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than EvoNext Holdings SA quarterly revenues of --. Roche Holding AG's net income of -- is lower than EvoNext Holdings SA's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 25.81x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.38x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.

Galderma Group AG has a net margin of -- compared to Roche Holding AG's net margin of --. Roche Holding AG's return on equity of 28.65% beat Galderma Group AG's return on equity of 4.9%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -90.33%. On the other hand Galderma Group AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Roche Holding AG has higher upside potential than Galderma Group AG, analysts believe Roche Holding AG is more attractive than Galderma Group AG.

Roche Holding AG has a beta of 0.270, which suggesting that the stock is 72.997% less volatile than S&P 500. In comparison Galderma Group AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.22%. Galderma Group AG offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. Galderma Group AG pays out -- of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Galderma Group AG quarterly revenues of --. Roche Holding AG's net income of -- is lower than Galderma Group AG's net income of --. Notably, Roche Holding AG's price-to-earnings ratio is 25.81x while Galderma Group AG's PE ratio is 130.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.38x versus 9.61x for Galderma Group AG. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 18.03%. Roche Holding AG's return on equity of 28.65% beat Novartis AG's return on equity of 32.47%.

Roche Holding AG has a consensus price target of --, signalling downside risk potential of -90.33%. On the other hand Novartis AG has an analysts' consensus of $140.30 which suggests that it could fall by -13.55%. Given that Roche Holding AG has more downside risk than Novartis AG, analysts believe Novartis AG is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.270, which suggesting that the stock is 72.997% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.176%.

Roche Holding AG has a quarterly dividend of $11.00 per share corresponding to a yield of 2.22%. Novartis AG offers a yield of 2.37% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 60.57% of its earnings as a dividend. Novartis AG pays out 42.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.3B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $2.4B. Notably, Roche Holding AG's price-to-earnings ratio is 25.81x while Novartis AG's PE ratio is 23.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 5.38x versus 6.01x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.